The series published by the group talks about the use of the now commonly used da Vinci™ surgical robotic system (Intuitive Surgicals, Inc.) for the excision of GIST, which are fairly large in size and/or difficult located tumours. Since the last two decades, globally, robotic-assisted minimally invasive surgery, especially for abdominopelvic surgeries, has taken off.\[[@ref1]\] Its use, especially in oncosurgery, to maintain the principles of resection to obtain negative margins for disease has been well established, more so in uro- and gynaec-oncology in recent times with well-documented literature evidence.\[[@ref2][@ref3]\]

However, the question here is, what is the message we are trying to give to the surgeons out there with respect to this particular issue. The case series is only a retrospective one with 12 cases done. On a comparative note, there is no data for the same provided by the team on their results with conventional laparoscopy. Today, we have technologies such as three-dimensional and 4K high-definition laparoscopy at our disposal which provide the same advantages of vision vis-à -vis the da Vinci™ robot. An experienced laparoscopy team will be able to provide the same or better results at a high-volume centre for the same procedures.\[[@ref4]\]

In addition, we are dealing with a malignant disease. A short-term follow-up is inadequate to state that the da Vinci™ robot is superior to any other technique because we are more concerned about long-term results in neoplasms rather than short-term recovery.

The crux of the issue is the cost factor for the use of the da Vinci™ robot, which is still prohibitive around the world. If the system is a public health/government-sponsored health scheme, one can use this technology freely. In most countries globally, the system prevailing is self-paying. This makes conventional laparoscopy a more time-tested and economical option than the robot.\[[@ref5]\]

A long-term randomised controlled trial comparing advanced laparoscopic techniques with the da Vinci™ robot needs to be designed in organ-specific procedures like these in order to determine the cost-benefit ratio and even long-term survival options for malignancies.
